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HUMAN MESENCHYMAL STROMAL CELLS ENHANCE METASTASIS OF
NEUROBLASTOMA VIA SDF-1/CXCR4 AND SDF-1/CXCR7 AXES
Ma, M., Chan, G.C.-F. The University of Hong Kong, Hong Kong SAR,
China
Background: Bone marrow is a frequent metastatic site for neuro-
blastoma, a common form of childhood cancer with poor progno-
sis. The SDF-1/CXCR4 axis has been proposed as an important
pathway during metastasis of neuroblastoma. But the role of
mesenchymal stromal cells (MSCs) and CXCR7, the other known
receptor for SDF-1, in metastatic neuroblastoma is yet to be
clarified.
Materials & Methods: In this study, we investigated the chemo-
tactic effects of human bone marrow derived MSCs on the migra-
tion of neuroblastma cells, with specific emphasis on the SDF-1/
CXCR4 and SDF-1/CXCR7 axes. To determine the contribution
of SDF-1 released by MSCs, we collected serum poor conditioned
media from three different MSC cultures and estimated their
SDF-1 levels by ELISA. We then examined the cell surface ex-
pression of CXCR4 and CXCR7 on five known neuroblastoma
cell lines (BE2C, BE2M17, IMR32, SK-N-LP and SY5Y) with
metastatic potential by flow cytometer. The metastatic functional
assessment was performed by transwell migration and invasion
assay.
Results: SDF-1 can be identified from the MSCs culture medium.
The migration and invasion of neuroblastoma was enhanced by
either MSCs co-culture or SDF-1 under transwell migration and
invasion assay. Flow cytometry analysis revealed that all of the
five cell lines expressed CXCR7, and four of them expressed
CXCR4. The migration efficiency of neuroblastoma cells in
response to either MSCs conditioned media or SDF-1 treatments
was considerably higher than that to control medium (n 5 3, p\
0.01), and such effect could be significantly blocked by
AMD3100, an inhibitor of CXCR4.
Conclusion: Our preliminary data suggested that MSCs enhanced
neuroblastoma cells migration and invasion and this is probably
acting through the SDF-1/CXCR4 and SDF-1/CXCR7 axes.187
STEM CELL DERIVED HEPATOCYTES AFTER CO-TRANSPLANTATION OF
MESENCHYMAL AND HEMATOPOIETIC STEM CELLS IN CLASS III BETA
THALASSEMIA MAJOR PATIENTS
Ghavamzadeh, A.1, Hamidieh, A.A.1, Shahi, F.1, Yaghmaei, M.1,
Seddighi, F.2, Tavangar, S.M.3, Jalili, M.1, Alimoghaddam, K.1 1Tehran
University of Medical Sciences, Tehran, Islamic Republic of Iran; 2Tehran
University of Medical Sciences, Tehran, Islamic Republic of Iran; 3Tehran
University of Medical Sciences, Tehran, Islamic Republic of Iran
Background: Bone marrow derived mesenchymal cells and stem
cells are potential to differentiate into mature cells of various organs.
Here we describe the initial results of study which suggests that these
cells transformed to hepatocytes.
Methods: In this prospective, single-center study during 18 months,
liver biopsy were obtained from 9 patients who had undergone Co-
Transplantation of Mesenchymal and Hematopoietic Stem Cell for
beta thalassemia major class III. Five female patients and 4 male
patients had received transplant from their sex mismatch donors.
The biopsies were studied for the presence of donor-derived hepato-
cytes with the use of fluorescence in situ hybridization (FISH) and
immunohistochemical staining (IHC) for CD45 (leukocyte common
antigen), and a hepatocyte-specific antigen.
Results: According to sex mismatch transplantation, mixed donor-
recipient XY-positive hepatocytes in liver specimen means that
new chimer stem cells were originated from donor cells. These cells
accounted for 8 to 70 percent of the cells on FISH slides and their
hepatocyte properities were shown by IHC methods.
Conclusions:Co-transplantation of Mesenchymal and Hematopoi-
etic Stem Cell can enhance regeneration of mature hepatocytes in
liver tissue.188
PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION OF MESENCHY-
MAL STEM CELLS DERIVED FROM PATIENTS AFFECTED BY SCHWACH-
MAN-DIAMOND SYNDROME
Andre, V.1, Longoni, D.2, Cipolli, M.3, Biondi, A.2, D’Amico, G.1 1 ’’M.
Tettamanti’’ Research Center, Pediatric Clinics, University of Milan-Bi-
cocca, Monza (MI), Italy; 2Pediatric Clinics, University of Milan-Bicocca,
San Gerardo Hospital, Monza (MI), Italy; 3Cystic Fibrosis Center, Ospe-
dale Civile Maggiore, Verona, Italy
Shwachman-Diamond Syndrome (SDS) is an inherited marrow
failure disorder characterized by varying cytopenias, pancreatic dys-
function, and metaphyseal dysostosis. Neutropenia plays a crucial
role in the occurrence of recurrent and severe infectious complica-
tions representing one of the major causes of death in SDS patients.
The aim of our study is to better comprehend the marrow dysfunc-
tion occurring in SDS patients, by analyzing the functional proper-
ties of bone marrow (BM)-derived mesenchymal stem cells (MSCs).
After informed consent, BM cells obtained from 16 SDS patients
were plated in sterile tissue culture flasks. At the third passage of
the culture, cells were tested for the expression of specific surface
markers, their ability to differentiate into mesengenic lineages, their
capability to abrogate T cell proliferation and their capacity to
prevent neutrophils apoptosis. MSCs derived from SDS patients
(SDS-MSCs) displayed typical fibroblastoid morphology; they
were consistently devoid of contaminating hematopoietic cells, be-
ing negative for CD34, CD45, HLA-DR, CD11b, CD19, and
CD14, but expressed common MSC markers including CD90,
CD73, CD105 and HLA-ABC. Similarly to MSCs obtained from
healthy donors (HD-MSCs), these cells were able to differentiate
into adipocytes and osteoblasts. In addition, SDS-MSCs drastically
decreased the mitogen-induced lymphocyte proliferation, in a dose
dependent manner. We also cultured neutrophils obtained from
HDs in presence or absence of MSCs at different time points. We
demonstrated that SDS-MSCs were comparable to HD-MSCs in
supporting the viability of neutrophils. Importantly, SDS-MSC
were able to produce high amount of IL-6 (mean 5 2658 pg/ml,
range5 2086-3229 pg/ml), a crucial cytokine involved in the protec-
tion of neutrophils from apoptosis.In conclusion, we successfully iso-
lated and characterizedMSCs from SDSpatients. These cells did not
show any significant differences from HD-MSCs. Further studies
are needed to better comprehend the functional and molecular fea-
tures of SDS-MSCs, which are potentially involved in the hemato-
logical abnormalities typical of SDS patients.189
STROMAL STEM CELL THERAPY FOR PROPHYLAXIS OF ACUTE GVHD:
PRELIMINARY RESULTS FROM A PHASE 1 TRIAL
Maziarz, R.T.1, Bachier, C.5, Goldstein, S.3, Devine, S.7, Leis, J.4,
Cooke, K.2, Perry, R.6, Van’t Hof, W.6, Deans, R.6, Lazarus, H.M.2 1Or-
egon Health & Science University, Portland, OR; 2University Hospitals
Case Medical Center, Cleveland, OH; 3University of Pennsylvania, Phil-
adelphia, PA; 4Mayo Clinic Hospital, Scottsdale, AZ; 5Texas Transplant
Institute, San Antonio, TX; 6Athersys, Cleveland, OH; 7Ohio State Uni-
versity, Columbus, OH
Background: Stromal stem cells are actively studied as a novel ad-
junct therapy after HSCT. Safety of mesenchymal stromal cells
was shown in early phase clinical trials with benefit for engraftment
and treatment of acute or steroid refractory GVHD (Lazarus 2005,
LeBlanc 2008, Kebriaei 2009). Phase III trials have reported mixed
outcomes for MSC therapy for acute or steroid refractory GVHD
(Martin 2010, Prasad 2010). Multipotent adult progenitor cells
(MultiStem) is a stromal stem cell source with similar immune-
modulatory activity as MSC and can be manufactured to clinical
scale allowing all patients on an individual study to be treated with
uniform allogeneic cell product from a universal donor. Pre-clinical
studies have demonstrated safety for iv infusion of MultiStem and
survival benefit in a haploidentical acute GVHD rat model when
used in a prophylactic manner (Kovacsovics 2008, 2009).
Methods: The primary goal of this open label Phase I clinical dose
escalation study is to assess safety of MultiStem in adult hematolog-
ical malignancy patients when administered shortly after allogeneic
HSCT. Patients with AML, ALL, CML, or MDS are enrolled in ei-
ther one of two study arms for MultiStem infusion at 1, 5 or 10
Poster Session I S223million/kg single dose on day 2 after HSCT (n 5 18), or in repeat
doses of 1 or 5 M/kg on days 2, 9, 16, or 5 M/kg on days 2, 9, 16,
23 and 30 (n 5 18).
Table 1. MultiStem dose escalation strategy
Single dose Arm Repeat dose Arm (Days 2, 9, 16
(Day 2 after HSCT) or 2, 9, 16, 23 and 30 after HSCT)1 Million cells/kg 1 Million cells/kg  3 infusions
5 Million cells/kg 5 Million cells/kg  3 infusions
10 Million cells/kg 5 Million cells/kg  5 infusionsInfusional toxicity and RRTs are assessed as safety parameters for 30
days after the last MultiStem dose. Secondary evaluations include in-
cidences of Grade III/IV acute GVHD and infection and survival
through day 100. Dose assignment is guided by the Continual Reas-
sessment Method.
Results: Single dose arm; 15 patients were enrolled from 4 clinical
centers. Multistem was infused at 1, 5 and 10 million/kg. At this
point there has been no observation of infusional toxicity. Enroll-
ment is scheduled for completion by December 2010. Repeat dose
arm; appr. half of the multiple dose cohorts to be enrolled at this
time. Details of primary endpoints and preliminary results for sec-
ondary endpoints will be presented for the single dose arm.
Summary:This Phase 1 trial of the stromal stem cell productMulti-
Stem is focused on safety of repeated infusion during the first weeks
after HSCT, the critical period for engraftment with high risk for
first onset of aGVHD. This strategy will be exploited to determine
if MultiStem therapy can be harnessed for a potential new therapeu-
tic option for GVHD prophylaxis after HSCT.190
INTERCELLULAR CYTOSOLIC TRANSFER CORRELATESWITHMESENCHY-
MAL STROMAL CELL (MSC) RESCUE OF UMBILICAL CORD BLOOD (UCB)
CELL VIABILITY DURING EX VIVO UCB EXPANSION
Chu, P.P.Y.1,2, Bari, S.3,5, Fan, X.4, Gay, F.P.H.5, Ang, J.M.L.5,
Chiu, G.N.C.6, Chan, C.K.3, Hwang, W.Y.K.1,2,5 1Singapore General
Hospital, Singapore, Singapore; 2Singapore Cord Blood Bank, Singapore,
Singapore; 3National University of Singapore, Singapore, Singapore;
4Singapore General Hospital, Singapore, Singapore; 5Duke-NUS Grad-
uate Medical School, Singapore, Singapore; 6National University of Sin-
gapore, Singapore, Singapore
Mesenchymal Stromal Cell (MSC) co-culture enhances ex vivo ex-
pansion of hematopoietic stem and progenitor cells from thawed
Umbilical Cord Blood (UCB) without prior CD341/CD1331 cell
selection. We hypothesized that the superior ex vivo expansion is
due to reversal of UCB c apoptosis via intercellular cytosolic transfer
from the MSC to the UCB cells. MSC endogenously expressing
green fluorescent protein (GFP) or exogenously labeled with quan-
tumdots (QDs)were co-culturedwithUCBcells positive for a hema-
topoietic-specific CD45 marker. Cultured UCB cells without MSC
layer served as control. Annexin-V, JC-1 dye & caspase inhibitors
were used to investigatemitochondria-associated apoptosis pathway.
Flow cytometry & confocal imaging were used to detect for the
transfer of the GFP or QD in co-cultured UCB cells. Thawed
UCB cells had high percentage of early apoptotic cells (defined by
Annexin-V positivity) which progressed to dead cells (defined by
7AAD positivity). MSC co-culture resulted in reversal of Annexin-
V positivity and reached a maximum on day 3 (viability defined by
double negative staining for Annexin-V and 7AAD) (p\0.05). A sig-
nificant reduction in caspase 3/7, 8& 9 activity as well as preservation
of mitochondrial membrane potential were observed in the co-cul-
tured UCB cells (p\ 0.05). Upon co-culture with GFP-expressing
or QD-labelled MSC, unlabelled UCB cells were found positive
for these markers as early as 24 hours post co-culture. The number
of GFP & CD45 positive UCB cells increased over the first 3 days
of co-culturing, which correlated with viability increase. Direct con-
tact betweenMSC&UCB was necessary for the transfer, as negligi-
ble transfer was observed when the two populations were separated
by transwell inserts. Separation also showed a significant decrease
in viability. The UCB cells that tightly adhered to the MSC layer
exhibited optimal transfer & cell viability. DNA analysis of the via-
ble, GFP transfer-positive UCB cells, as determined by VariableNumber Tandem Repeat analysis ruled out the possibilities of
MSC trans-differentiation or MSC-UCB fusion. In addition, there
was statistical correlation between higher levels of cytosolic transfer
and enhanced UCB cell viability (p \ 0.0001). The above data
provides evidence that intercellular transfer of cytosolic materials




CLINICAL OUTCOMES OF HAPLOIDENTICAL DONOR COMPARED WITH
UNRELATED AND HLA-MATCHED RELATED DONOR HEMATOPOIETIC
STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES
Luo, Y., Tan, Y., Hu, Y., Shi, J., Zheng, G., Zheng, W., Huang, H.
The First Affiliated Hospital, Zhejiang University School of Medicine,
Hangzhou, Zhejiang Province, China
Introduction: In clinical trials, an HLA-matched donor can be
found for about 50% to 60% of patients referred for HSCT which
greatly limits the application of allogeneic HSCT. Haploidentical
HSCTwould increase the availability of a donor to 100%.However,
haploidentical HSCTmay be associated with high risks of complica-
tions, such as graft rejection, severe GVHD and infection etc. Much
progress have been made due to advanced technologies applied in
haploidentical HSCT.
Materials and Methods: For haploidentical HSCT, conditioning
regimen consisted of Ara-C (4 g/m2/d) on day -10 and -9, Bu
(9.6mg/kg) on day -8, -7 and -6, Cy (1.8 g/m2/d) on day -5 and -4,
Me-CCNU (250 mg/kg) on day -3, and ATG (2.5 mg/kg/d) on
day -5 to -2. For unrelated and matched related HSCT, the condi-
tioning regimen consisted of Bu (0.8mg/kg -7d to -4d), Cy (60mg/
kg /d -3d and -2d). GVHD prophylaxis consisted of cyclosporine
A (CsA), mycophenolate mofetil (MMF), and short-termmethotrex-
ate while ATG were added in HLA-mismatched unrelated HSCT.
The data of 114 patients (38 with haploidentical donors, 35 with
HLA-matched related donors and 63 with unrelated donors) were
analyzed .
Results: The incidence of grade II–IV aGVHD was 36.8% in the
haploidentical group, 40.5% in the unrelated group and 22.9% in
the related matched group (p. 0.05 between haploidentical and un-
related, haloidentical and related matched group; p 5 0.0477 be-
tween urelated and related matched group). The 1 year OS were
68.4%, 78.4% and 91.3% in haploidentical, unrelated and relate
matched group respectively(p . 0.05 among the 3 groups). The 1
year TRM were 15.8%, 6.3% and 0% in haploidentical, unrelated
and related matched group respectively(p\0.0162 between haploi-
dentical and relatedmatched group; p. 0.05 between haploidentical
and unrelated, unrelated and matched related group).
Conclusions: There is a trend that survival in haploidentical group
and unrelated group is inferior to matched related group in patients
despite of statistical insignificance. AnHLA-matchedHSCT is com-
monly the preferred transplantation and donors fromHLA-matched
related siblings are usually the first choice. Haploidentical stem cell
transplantation is relatively safe and efficient for patients who do not
have HLA matched donors.192
A COST-BENEFIT ANALYSES COMPARING HAPLOIDENTICAL TRANSPLAN-
TATION WITH HLA MATCHED SIBLING AND URD IN HEMATOLOGICAL
MALIGNANCIES
Dong, L.1, Gao, Z.1, Zhang, M.-J.2, Tang, X.1, Liu, J.1, Yu, X.1,
Zhou, L.1, Xie, Y.1, Lu, D.1 1Fu Dan University, Shanghai Dao-Pei
Hospital, Shanghai, China; 2CIBMTR, Medical College of Wisconsin,
Milwaukee, WI
Background: Haploidentical (haplo) stem cell transplantation has
demonstrated intensive graft vs. leukemia effect and survival advan-
tage in patients with advanced leukemia. However, early virus reac-
tivation and acute GVHD may dramatically increase the cost of
treatment. Here we investigate the impact of donor types on clinical
outcomes and cost of treatment within 100 days of transplant.
